Journal of Thrombosis and Thrombolysis

, Volume 36, Issue 1, pp 109–114 | Cite as

Acquired FXIII inhibitors: a systematic review

  • Massimo Franchini
  • Francesco Frattini
  • Silvia Crestani
  • Carlo Bonfanti
Article

Abstract

Coagulation factor XIII (FXIII) is a protein that promotes fibrin stabilization by forming multiple covalent cross-links between fibrin monomers. Beside congenital FXIII deficiency, due to FXIII gene mutations, severe acquired FXIII deficiency has been described in association with autoantibodies against coagulation FXIII. These inhibitors, which occurs very rarely but may cause life-threatening bleeding complications, may arise spontaneously or in association with autoimmune and lymphoproliferative disorders or medications. The management of patients with acquired FXIII inhibitors is very demanding and treatment regimens must be focused on eradication of the inhibitor and to increase the plasma FXIII levels. In this systematic review, we analyse all the published case-reports on anti-FXIII autoantibodies focusing on the clinical features and treatment modalities of this acquired hemorrhagic condition.

Keywords

Factor XIII Inhibitors Autoantibodies Bleeding Therapy 

References

  1. 1.
    Lorand L, Losowsky MS, Miloszewski KJ (1980) Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb 5:245–290PubMedGoogle Scholar
  2. 2.
    Schwartz ML, Pizzo SV, Hill RL, McKee PA (1973) Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 248:1395–1407PubMedGoogle Scholar
  3. 3.
    Koseki-Kuno S, Yamakawa M, Dickneite G, Ichinose A (2003) Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood 102:4410–4412PubMedCrossRefGoogle Scholar
  4. 4.
    Takagi T, Doolittle RF (1974) Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry 13:750–756PubMedCrossRefGoogle Scholar
  5. 5.
    Ichinose A, Davie EW (1988) Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci USA 85:5829–5833PubMedCrossRefGoogle Scholar
  6. 6.
    Webb GC, Coggan M, Ichinose A, Board PG (1989) Localization of the coagulation factor XIII B subunit gene (F13B) to chromosome bands 1q31-32.1 and restriction fragment length polymorphism at the locus. Hum Genet 81:157–160PubMedCrossRefGoogle Scholar
  7. 7.
    Board PG, Losowsky MS, Miloszewski KJA (1993) Factor XIII: inherited and acquired deficiency. Blood Rev 7:229–242PubMedCrossRefGoogle Scholar
  8. 8.
    Hsieh L, Nugent D (2008) Factor XIII deficiency. Haemophilia 14:1190–1200PubMedCrossRefGoogle Scholar
  9. 9.
    Karimi M, Bereczky Z, Cohan N, Muszbek L (2009) Factor XIII deficiency. Semin Thromb Hemost 35:426–438PubMedCrossRefGoogle Scholar
  10. 10.
    Lorand L (2005) Factor XIII and the clotting of fibrinogen: from basic research to medicine. J Thromb Haemost 3:1337–1348PubMedCrossRefGoogle Scholar
  11. 11.
    Ichinose A (2011) Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 37:382–388PubMedCrossRefGoogle Scholar
  12. 12.
    Lewis JH, Szeto IL, Ellis LD, Bayer WL (1967) An acquired inhibitor to coagulation factor 13. Johns Hopkins Med J 120:401–407PubMedGoogle Scholar
  13. 13.
    Lorand L, Jacobsen A, Bruner-Lorand J (1968) A pathological inhibitor of fibrin cross-linking. J Clin Investig 47:268–273PubMedCrossRefGoogle Scholar
  14. 14.
    Godal HC (1970) An inhibitor to fibrin stabilizing factor (FSF, factor XIII). Scand J Haematol 7:43–48PubMedCrossRefGoogle Scholar
  15. 15.
    Lorand L, Maldonado N, Fradera J, Atencio AC, Robertson B, Urayama T (1972) Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol 23:17–27PubMedCrossRefGoogle Scholar
  16. 16.
    Lopaciuk S, Bykowska K, McDonagh JM et al (1978) Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Investig 61:1196–1203PubMedCrossRefGoogle Scholar
  17. 17.
    McDevitt NB, McDonagh J, Taylor HL, Roberts HR (1972) An acquired inhibitor to factor XIII. Arch Intern Med 130:772–777PubMedCrossRefGoogle Scholar
  18. 18.
    Graham JE, Yount WJ, Roberts HR (1973) Immunochemical characterization of a human antibody to factor XIII. Blood 41:661–669PubMedGoogle Scholar
  19. 19.
    Otis PT, Feinstein DI, Rapaport SI, Patch MJ (1974) An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood 44:771–781PubMedGoogle Scholar
  20. 20.
    Rosenberg RD, Colman RW, Lorand L (1974) A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Br J Haematol 26:269–284PubMedCrossRefGoogle Scholar
  21. 21.
    Milner GR, Holt PJ, Bottomley J, Maciver JE (1977) Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 30:770–773PubMedCrossRefGoogle Scholar
  22. 22.
    Shires L, Gomperts ED, Bradlow BA (1979) An acquired inhibitor to factor XIII A case report. S Afr Med J 56:70–72PubMedGoogle Scholar
  23. 23.
    Fear JD, Miloszewski KJ, Losowsky MS (1984) An acquired inhibitor of factor XIII with a qualitative abnormality of fibrin crosslinking. Acta Haematol 71:304–309PubMedCrossRefGoogle Scholar
  24. 24.
    Nakamura S, Kato A, Sakata Y, Aoki N (1988) Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 68:313–319PubMedCrossRefGoogle Scholar
  25. 25.
    Lorand L, Velasco PT, Rinne JR et al (1988) Autoimmune antibody (IgG Kansas) against the fibrin stabilizing (factor XIII) system. Proc Natl Acad Sci USA 85:232–236PubMedCrossRefGoogle Scholar
  26. 26.
    Daly HM, Carson PJ, Smith JK (1991) Intracerebral haemorrhage due to acquired factor XIII inhibitor—successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 2:507–514PubMedCrossRefGoogle Scholar
  27. 27.
    Krumdieck R, Shaw DR, Huang ST, Poon MC, Rustagi PK (1991) Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenstrom’s macroglobulinemia. Am J Med 90:639–645PubMedGoogle Scholar
  28. 28.
    Gailani D (1992) An IgG inhibitor against coagulation factor XIII: resolution of bleeding after plasma immunoadsorption with staphylococcal protein A. Am J Med 92:110–112PubMedCrossRefGoogle Scholar
  29. 29.
    Fukue H, Anderson K, McPhedran P, Clyne L, McDonagh J (1992) A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA. Blood 79:65–74PubMedGoogle Scholar
  30. 30.
    Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T (1995) An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 48:34–39PubMedCrossRefGoogle Scholar
  31. 31.
    Ahmad F, Solymoss S, Poon MC, Berube C, Sullivan AK (1996) Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol 93:700–703PubMedCrossRefGoogle Scholar
  32. 32.
    Lorand L, Velasco PT, Murthy SN, Lefebvre P, Green D (1999) Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood 93:909–917PubMedGoogle Scholar
  33. 33.
    Lorand L, Velasco PT, Hill JM, Hoffmeister KJ, Kaye FJ (2002) Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against factor XIII. Thromb Haemost 88:919–923PubMedGoogle Scholar
  34. 34.
    Lim W, Moffat K, Hayward CPM (2004) Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2:1017–1019PubMedCrossRefGoogle Scholar
  35. 35.
    Miesbach W (2005) Rituximab in the treatment of factor XIII inhibitor possibly caused by ciprofloxacin. Thromb Haemost 93:1001–1003PubMedGoogle Scholar
  36. 36.
    Gregory TF, Cooper B (2006) Case report of an acquired factor XIII inhibitor: diagnosis and management. Proc (Bayl Univ Med Cent) 19:221–223Google Scholar
  37. 37.
    Ajzner E, Schlammadinger A, Kerényi A et al (2009) Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 113:723–725PubMedCrossRefGoogle Scholar
  38. 38.
    Ishida F, Okubo K, Ito T, Okumura N, Souri M, Ichinose A (2010) Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency. Thromb Haemost 104:1284–1285PubMedCrossRefGoogle Scholar
  39. 39.
    Luo Y, Zhang G, Zuo W, Zheng W, Dai C (2010) Acquired factor XIII inhibitor in monoclonal gammopathy of undetermined significance: characterization and cross-linked fibrin ultrastructure. Ann Hematol 89:833–834PubMedCrossRefGoogle Scholar
  40. 40.
    Luo Y, Zhang G (2011) Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination. Haemophilia 17:393–398PubMedCrossRefGoogle Scholar
  41. 41.
    Hayashi T, Kadohira Y, Morishita E, Asakura H, Souri M, Ichinose (2012) A case of acquired FXIII deficiency with severe bleeding symptoms. Haemophilia 18:618–620PubMedCrossRefGoogle Scholar
  42. 42.
    Ichinose A, Souri M, Japanese collaborative research group on “Acquired haemorrha-philia due to factor XIII deficiency” (2011) As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 105:925–927PubMedCrossRefGoogle Scholar
  43. 43.
    Tosetto A, Castaman G, Rodeghiero F (1993) Acquired plasma factor XIII deficiencies. Haematologica 78(Suppl. 6):5–10PubMedGoogle Scholar
  44. 44.
    Franchini M, Lippi G, Favaloro EJ (2012) Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost 38:447–453PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Massimo Franchini
    • 1
  • Francesco Frattini
    • 1
  • Silvia Crestani
    • 1
  • Carlo Bonfanti
    • 1
  1. 1.Department of Transfusion Medicine and HematologyCarlo Poma HospitalMantuaItaly

Personalised recommendations